A post hoc sub-analysis of the REDUCE-IT Study.published in the Journal of the American Heart Association (JAHA).has found that Vascepa (icosapent ethyl) signif 11 March 2022
Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) has been granted a marketing authorisation by the European Medicines Agency (EMA) for the treatme 7 March 2022
A new broader label for heart med Jardiance (empagliflozin) will help developers Eli Lilly and Boehringer Ingelheim extend the increasingly lucrative franchise. 25 February 2022
The High Court in London has ruled against attempts by Servier to limit damages it owes for infringements of competition law in the sale and supply of a widely- 22 February 2022
Dutch thrombotic diseases specialist TargED Biopharmaceuticals has raised 39 million euros ($44 million) in a Series A financing to accelerate development of it 22 February 2022
Chinese biopharma firm Innovent Biologics has announced that its experimental anti-PCSK9 antibody, named IBI306, has come up trumps in two Phase III trials in C 18 February 2022
California’s Cytokinetics has announced topline results from the METEORIC-HF Phase III trial of omecamtiv mecarbil in patients with heart failure with reduced e 16 February 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.